Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of PF-04965842 versus dupilumab versus placebo with background topical therapy in adults with moderate to severe atopic dermatitis
2018-002573-21Phase 3Completed
- Sponsor
- Pfizer
- Start
- Nov 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of abrocitinib and dupilumab in atopic dermatitis (AD) (4 arms), sponsored by Pfizer. Primary endpoint: Investigator's Global Assessment response at Week 12. Started Nov 2018; status: completed.
02
Drugs
abrocitinibdupilumab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on 2018-002573-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002573-21.